updat model g-estrac cream
updat model g-estrac cream approv
updat estim rais po reflect myl recent
approv gener estrac cream allergan women health brand net
sale recent launch g-estrac follow author gener launch
teva assum two-gener market maintain estim approv
add sale base updat believ
better posit achiev aspir non-gaap ep target
forecast go forward view risk/reward around key
catalyst gener copaxon advair opportun balanc reiter
blockbust gx competit limit
estrac cream off-pat sinc march without gener altern
gener believ like enjoy semi-exclus market dynam
next year given cost hurdl gener bioequival studi
estrac enrol subject studi initi june
complet decemb base compani check topic gener clinic trial
cost significantli expens typic oral solid
dosag product closest competitor includ alvogen like file
anda earli base complet date ct gov initi market
two gener forecast price discount gener rel
current net price forecast achiev share
reiter neutral rate thesi
remain neutral rate see balanc invest posit
neg pro includ upsid number g-copaxon remain sole-
sourc exclus gener version gsk advair approv
neg includ headwind mylan us legaci gener base busi and/or
competitor approv gener copaxon levo could repres downsid near-
term estim also cautiou growth profil myl intern
generic/otc busi enter first true y/i report period segment
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharmaceut compani
develop manufactur market
pharmaceut product span three segment
gener over-the-count brand specialti
product north american biggest market
account approxim total
sale follow europ
remaind rest world becom
one largest specialti gener player
combin organ growth
number signific acquisit
neutral balanc
invest posit neg stock
like prospect organ growth us
copaxon potenti upsid gener
approv advair restasi convers
concern around headwind gener
busi well aggress assumpt
compani guidanc impli cost
cut deal may may drive
long-term valu sharehold
price object po base multipl ebitda
rel gener peer believ share trade
similar multipl gener peer lower closest peer teva latter
benefit low trough year uptick clinic de-risk spec
brand furthermor less visibl earn profil
view compani gener growth driver less durabl sourc growth
teva key spec brand believ dcf appropri valuat methodolog
littl visibl outlook beyond one two year
multipl take follow consider enjoy gener
exclus copaxon approv g-advair gener advair
low- mid-single-digit growth eu row busi
risk po approv g-advair greater-than-expect competit
pressur copaxon gener
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
